Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.

Cancer immunology, immunotherapy : CII - 1 Oct 2012

Zhang Haihong, Wang Yuqian, Liu Chenlu, Zhang Lixing, Xia Qiu, Zhang Yong, Wu Jiaxin, Jiang Chunlai, Chen Yan, Wu Yongge, Zha Xiao, Yu Xianghui, Kong Wei

Abstract excerpt

Survivin is overexpressed in major types of cancer and is considered an ideal "universal" tumor-associated antigen that can be targeted by immunotherapeutic vaccines. However, its anti-apoptosis function raises certain safety concerns. Here, a new truncated human survivin, devoid of the anti-apoptosis function, was generated as a candidate tumor vaccine. Interleukin 2 (IL-2) has been widely used as an adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adjuvants, Immunologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Carboplatin

Share to Inhibitor of Apoptosis Proteins

Share to Melanoma, Experimental

Share to Survivin

Share to Vaccines, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 22706381
DOI: 10.1007/s00262-012-1296-3
PMCID: PMC11028718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.PMID 22706381Read ↗

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read ↗

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.Semantic proximity Read ↗

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1Semantic proximity Read ↗

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.Semantic proximity Read ↗

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeuticSemantic proximity Read ↗

Adenovirus as vehicle for anticancer genetic immunotherapySemantic proximity Read ↗

Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activationSemantic proximity Read ↗

Survivin as a target for new anticancer interventions.Semantic proximity Read ↗

Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine.Semantic proximity Read ↗

Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.Semantic proximity Read ↗

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.Semantic proximity Read ↗

Interferon-β-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.